These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 24982550)

  • 1. Effect of oral administration of unfractionated heparin (UFH) on coagulation parameters in plasma and levels of urine and fecal heparin in dogs.
    Erickson M; Hiebert LM; Carr AP; Stickney JD
    Can J Vet Res; 2014 Jul; 78(3):193-201. PubMed ID: 24982550
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased plasma anti-Xa activity and recovery of heparin from urine suggest absorption of orally administered unfractionated heparin in human subjects.
    Hiebert LM; Wice SM; Ping T
    J Lab Clin Med; 2005 Mar; 145(3):151-5. PubMed ID: 15871307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
    Brooks MB
    Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sonoclot® evaluation of single- and multiple-dose subcutaneous unfractionated heparin therapy in healthy adult dogs.
    Babski DM; Brainard BM; Ralph AG; Pittman JR; Koenig A
    J Vet Intern Med; 2012; 26(3):631-8. PubMed ID: 22435404
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring.
    Vandiver JW; Vondracek TG
    Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anticoagulant effects of inhaled unfractionated heparin in the dog as determined by partial thromboplastin time and factor Xa activity.
    Manion JS; Thomason JM; Langston VC; Claude AK; Brooks MB; Mackin AJ; Lunsford KV
    J Vet Emerg Crit Care (San Antonio); 2016; 26(1):132-6. PubMed ID: 26194053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Agreement between activated partial thromboplastin time and anti-Xa activity in critically ill patients receiving therapeutic unfractionated heparin.
    Ratano D; Alberio L; Delodder F; Faouzi M; Berger MM
    Thromb Res; 2019 Mar; 175():53-58. PubMed ID: 30708169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of inhibition of the prothrombinase complex by a covalent antithrombin-heparin complex.
    Stevic I; Berry LR; Chan AK
    J Biochem; 2012 Aug; 152(2):139-48. PubMed ID: 22518847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of a therapeutic dose of unfractionated heparin (200 U/kg) administered subcutaneously or intravenously to healthy dogs.
    Diquélou A; Barbaste C; Gabaig AM; Trumel C; Abella-Bourges N; Guelfi JF; Bousquet Mélou A
    Vet Clin Pathol; 2005 Sep; 34(3):237-42. PubMed ID: 16134071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs.
    Mischke R; Grebe S; Jacobs C; Kietzmann M
    Am J Vet Res; 2001 Apr; 62(4):595-8. PubMed ID: 11327470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo age dependency of unfractionated heparin in infants and children.
    Newall F; Ignjatovic V; Summerhayes R; Gan A; Butt W; Johnston L; Monagle P
    Thromb Res; 2009 Mar; 123(5):710-4. PubMed ID: 18829072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Establishing a new target range for unfractionated heparin for acute coronary syndromes.
    Lee MS; Menon V; Schappert J; Wilentz JR; Singh V; Hochman JS
    J Thromb Thrombolysis; 2004 Apr; 17(2):121-6. PubMed ID: 15306747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Theophylline adenosine dipyridamole (CTAD) and citrate evaluation to survey unfractionated heparin treatment: a delayed centrifugation validation for anti-Xa measurement?].
    Billoir P; Clavier T; Guilbert A; Barbay V; Chrétien MH; Fresel M; Abriou C; Girault C; Le Cam Duchez V
    Ann Biol Clin (Paris); 2020 Feb; 78(1):27-34. PubMed ID: 32108577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How to use unfractionated heparin to treat neonatal thrombosis in clinical practice.
    Bhatt MD; Paes BA; Chan AK
    Blood Coagul Fibrinolysis; 2016 Sep; 27(6):605-14. PubMed ID: 26656898
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activated partial thromboplastin time and anti-xa measurements in heparin monitoring: biochemical basis for discordance.
    Takemoto CM; Streiff MB; Shermock KM; Kraus PS; Chen J; Jani J; Kickler T
    Am J Clin Pathol; 2013 Apr; 139(4):450-6. PubMed ID: 23525615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The APTT response of pregnant plasma to unfractionated heparin.
    Chunilal SD; Young E; Johnston MA; Robertson C; Naguit I; Stevens P; Galashan D; Oskamp ML; Brennan B; Ginsberg JS
    Thromb Haemost; 2002 Jan; 87(1):92-7. PubMed ID: 11848463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anticoagulant effects of repeated subcutaneous injections of high doses of unfractionated heparin in healthy dogs.
    Mischke RH; Schüttert C; Grebe SI
    Am J Vet Res; 2001 Dec; 62(12):1887-91. PubMed ID: 11763176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of the prothrombinase complex on red blood cells by heparin and covalent antithrombin-heparin complex.
    Stevic I; Chan HH; Berry LR; Chander A; Chan AK
    J Biochem; 2013 Jan; 153(1):103-10. PubMed ID: 23100269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate.
    Cosmi B; Fredenburgh JC; Rischke J; Hirsh J; Young E; Weitz JI
    Circulation; 1997 Jan; 95(1):118-24. PubMed ID: 8994426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The establishment and validation of efficient assays for anti-IIa and anti-Xa activities of heparin sodium and heparin calcium.
    Suzuki T; Ishii-Watabe A; Hashii N; Nakagawa Y; Takahashi T; Ebisawa A; Nishi S; Fujita N; Bando A; Sekimoto Y; Miyata K; Endo T; Otsu T; Sugimoto S; Kondou T; Fujita Y; Miyanaga N; Mashimo M; Shimada N; Yoden H; Shimamura H; Kurata Y; Koyama S; Kawasaki N
    Biologicals; 2013 Nov; 41(6):415-23. PubMed ID: 24095600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.